ReciBioPharm attains Bill & Melinda Gates Foundation grant to achieve continuous RNA manufacturing

Published: 21-Jan-2025

The biologics CDMO hopes to bring RNA medicines to more patients globally by providing its xRNA continuous manufacturing technology to lower and middle income countries

Biologics CDMO division of Recipharm, ReciBioPharm, has obtained a grant from the Bill & Melinda Gates Foundation.

The funding will support the global deployment of the company's xRNA continuous manufacturing technologies, with a specific focus on lower to middle income countries.

ReciBioPharm will primarily look to provide its technology to countries with inline process analytical and predictive analytic capabilities.

This aligns with the company's mission to optimise the quality, scalability and accessibility of RNA medicines globally.

Vikas Gupta, President of ReciBioPharm, said: “This grant represents a significant milestone in our commitment to advancing RNA manufacturing technologies that meet FDA standards. We are proud to lead this transformative effort, expanding access to RNA-based solutions for underserved regions.”

 “Our previously-announced collaboration with MIT has underscored the potential of continuous manufacturing for RNA therapeutics,” added Aaron Cowley, Chief Scientific Officer of ReciBioPharm. “This grant will help to strengthen our role as a pioneer in innovation and support our mission to make lifesaving technologies more accessible.”  

Via this project, ReciBioPharm hopes to address global health challenges through the combination of advanced technologies and scalable processes with GMP standards.

 

You may also like